Press Release


Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Apr 12, 2021 12:16 JST
Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021.
More info..

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
Mar 31, 2021 20:22 JST
KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei.
More info..

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
Mar 31, 2021 20:18 JST
Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA.
More info..

Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
Mar 30, 2021 11:42 JST
Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab.
More info..

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
Mar 26, 2021 08:16 JST
Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.
More info..

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
Mar 23, 2021 17:34 JST
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
More info..

Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
Mar 22, 2021 12:13 JST
Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
More info..

Eisai Awarded The New Diversity Management Selection 100
Mar 22, 2021 09:38 JST
Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program.
More info..

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders
Mar 17, 2021 10:05 JST
Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells.
More info..

Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu
Mar 16, 2021 10:37 JST
Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research between Eisai and University College London, has been selected by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).
More info..

Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer
Mar 12, 2021 10:08 JST
Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).
More info..

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease
Mar 05, 2021 16:51 JST
Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta protofibril antibody lecanemab, will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
More info..

Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya
Mar 04, 2021 08:12 JST
Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya.
More info..

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
Mar 02, 2021 08:06 JST
Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
More info..

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
Feb 22, 2021 14:40 JST
Eisai Co., Ltd. announced that it has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor E7090, which is currently under development as an orally available novel anti-cancer agent.
More info..

Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
Feb 22, 2021 12:11 JST
Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo).
More info..

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Feb 15, 2021 10:07 JST
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the first presentation of new investigational data from the pivotal Phase 3 CLEAR study (Study 307/KEYNOTE-581) in an oral presentation session (Abstract #269) at the virtual 2021 Genitourinary Cancers Symposium (ASCO GU) and simultaneously published in the New England Journal of Medicine.
More info..

Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea
Feb 01, 2021 08:35 JST
Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). This is the first launch of Equfina in the Asian region excluding Japan.
More info..

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
Jan 26, 2021 10:58 JST
Eisai Co., Ltd. announced that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
Jan 12, 2021 11:37 JST
Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.
More info..

Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
Dec 18, 2020 12:09 JST
Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
More info..

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
Dec 17, 2020 11:47 JST
These positive results were observed in the mismatch repair proficient (pMMR) subgroup and the intention-to-treat (ITT) study population, which includes both patients with endometrial carcinoma that is pMMR as well as patients whose disease is microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR).
More info..

Eisai: Biogen Files New Drug Application for Aducanumab in Japan
Dec 11, 2020 09:43 JST
Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer's disease.
More info..

Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium
Dec 04, 2020 11:17 JST
The results of analysis evaluating eribulin in the clinical practice in a subgroup of patients with metastatic breast cancer with a poor prognosis, in the United States, (Abstract No: PS13-37) will be published.
More info..

Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
Nov 30, 2020 13:04 JST
Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
More info..

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
Nov 30, 2020 10:16 JST
Eisai Co., Ltd. and Wren Therapeutics Ltd. today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target alpha-synuclein for the potential treatment of synucleinopathies including Parkinson's disease and dementia with Lewy bodies.
More info..

AbbVie and Eisai Announce an approval for additional indication of HUMIRA
Nov 27, 2020 21:05 JST
This indication counts for HUMIRA's 12th indication in Japan and makes HUMIRA the world's first drug indicated for the treatment of PG.
More info..

Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
Nov 18, 2020 19:11 JST
Eisai Co., Ltd. announced today that it has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai?s seventh selection.
More info..

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
Nov 18, 2020 19:00 JST
Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18.
More info..

Latest Release


More Latest Release >>